Physical exercise shows neuroprotective and anti-inflammatory effects in Alzheimer's disease (AD) models, but whether it modulates neuroinflammation through regulation of peripheral T-cell activity is still unresolved.
Objective
The present study aimed to explore the mechanisms by which aerobic exercise regulates peripheral T cell-mediated immune responses and their potential contribution to neuroinflammation in AD.
Methods
Male wild-type mice and APP/PS1 transgenic mice were divided into four groups: wild-type sedentary mice (WT-SE) group, wild-type exercise group (WT-EX), APP/PS1 transgenic AD sedentary mice (AD-SE) group, and APP/PS1 transgenic AD exercise mice (AD-EX) group. The sedentary groups received no exercise training, while the exercise groups underwent a 3-month treadmill aerobic exercise intervention. At the end of the intervention, T lymphocytes were isolated from spleens. Label-free proteomics combined with LC-MS/MS was used to identify differentially expressed proteins (DEPs) and perform functional and pathway enrichment analyses. Differentially expressed protein-coding genes were validated at the mRNA level using RT-qPCR.
Results
A total of 3399 proteins were quantified across the four groups. Applying a threshold of |log2 fold change| > 0.67 and q-value < 0.05, 913 DEPs were identified. These DEPs were significantly enriched in biological processes including immune system processes, protein-containing complexes, and structural molecule activity, as well as signaling pathways including AD, TGF-β, and apoptosis.
Conclusions
Overall, HSP90AB1, HSP90AA1, BAG5, DNAJC8, CTSD, and ANXA1 may play a role in peripheral T-cell immune dysregulation in AD, with potential implications for central neuroinflammation. Furthermore, the beneficial effects of aerobic exercise on AD-related peripheral immune alterations, and its potential modulation of neuroinflammation, may be associated with expression changes in DEPs including Ppp2r1b, Pde2a, Casp8, Apaf-1, Dnajb11, and Dnajc13.
SuYLiuNSunR, et al.Radix rehmanniae praeparata (shu dihuang) exerts neuroprotective effects on icv-stz-induced Alzheimer’s disease mice through modulation of insr/irs-1/akt/gsk-3β signaling pathway and intestinal microbiota. Front Pharmacol2023; 14: 1115387.
3.
SangZWangKBaiP, et al.Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer’s disease. Eur J Med Chem2020; 194: 112265.
4.
PhilipsonOLordAGumucioA, et al.Animal models of amyloid-β-related pathologies in Alzheimer’s disease. FEBS J2010; 277: 1389–1409.
5.
Serrano-PozoAFroschMPMasliahE, et al.Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med2011; 1: a006189.
6.
KinneyJWBemillerSMMurtishawAS, et al.Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y)2018; 4: 575–590.
7.
ThakurSDhapolaRSarmaP, et al.Neuroinflammation in Alzheimer’s disease: current progress in molecular signaling and therapeutics. Inflammation2023; 46: 1–17.
8.
WojdaU. Alzheimer's disease lymphocytes: potential for biomarkers?Biomark Med2016; 10: 1–4.
9.
BettcherBMTanseyMGDorothéeG, et al.Peripheral and central immune system crosstalk in Alzheimer disease—a research prospectus. Nat Rev Neurol2021; 17: 689–701.
10.
FerrettiMTMerliniMSpaniC, et al.T-cell brain infiltration and immature antigen-presenting cells in transgenic models of Alzheimer's disease-like cerebral amyloidosis. Brain Behav Immun2016; 54: 211–225.
11.
KorinBBen-ShaananTLSchillerM, et al.High-dimensional, single-cell characterization of the brain's immune compartment. Nat Neurosci2017; 20: 1300–1309.
12.
RitzelRMCrapserJPatelAR, et al.Age-associated resident memory CD8T cells in the central nervous system are primed to potentiate inflammation after ischemic brain injury. J Immunol2016; 196: 3318–3330.
13.
MerliniMKirabaliTKulicL, et al.Extravascular CD3+ T cells in brains of Alzheimer disease patients correlate with tau but not with amyloid pathology: an immunohistochemical study. Neurodegener Dis2018; 18: 49–56.
14.
TogoTAkiyamaHIsekiE, et al.Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol2002; 124: 83–92.
15.
JevticSSengarASSalterMW, et al.The role of the immune system in Alzheimer disease: etiology and treatment. Ageing Res Rev2017; 40: 84–94.
16.
UngerMSMarschallingerJKaindlJ, et al.Doublecortin expression in CD8+ T-cells and microglia at sites of amyloid-β plaques: a potential role in shaping plaque pathology?Alzheimers Dement2018; 14: 1022–1037.
17.
UngerMSchernthanerPMarschallingerJ, et al.Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice. J Neuroinflammation2018; 15: 1–23.
18.
DansokhoCAit AhmedDAidS, et al.Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain2016; 139: 1237–1251.
19.
MarshSEAbudEMLakatosA, et al.The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A2016; 113: E1316–E1325.
20.
FengYBoXBiaoH, et al.Biological mechanism of exercise remitting Alzheimer's disease and ameliorating recognition. J Shanghai Univ Sport2017; 41: 25–31.
21.
BrownBMRainey-SmithSRDoreV, et al.Self-reported physical activity is associated with tau burden measured by positron emission tomography. J Alzheimers Dis2018; 63: 1299–1305.
22.
YanglinJXianzeWKangL, et al.Research progress of exercise regulated microglia to delay Alzheimer's disease. Chem Life2021; 41: 1981–1988.
23.
SangHYaoSZhangL, et al.Walk-run training improves the anti-inflammation properties of high-density lipoprotein in patients with metabolic syndrome. J Clin Endocrinol Metab2015; 100: 870–879.
24.
PetersenAMWPedersenBK. The anti-inflammatory effect of exercise. J Appl Physiol2005; 98: 1154–1162.
25.
WangMZhangHLiangJ, et al.Exercise suppresses neuroinflammation for alleviating Alzheimer’s disease. J Neuroinflammation2023; 20: 76.
26.
ChoiSHBylykbashiEChatilaZK, et al.Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer’s mouse model. Science2018; 361: eaan8821.
27.
LourencoMVFrozzaRLde FreitasGB, et al.Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models. Nat Med2019; 25: 165–175.
28.
ZhaoNZhangXSongC, et al.The effects of treadmill exercise on autophagy in hippocampus of APP/PS1 transgenic mice. Neuroreport2018; 29: 819–825.
29.
ZhaoNYanQWXiaJ, et al.Treadmill exercise attenuates Aβ-induced mitochondrial dysfunction and enhances mitophagy activity in APP/PS1 transgenic mice. Neurochem Res2020; 45: 1202–1214.
30.
KeowkaseRAboukhatwaMAdamBL, et al.Neuroprotective effects and mechanism of cognitive-enhancing choline analogs JWB 1-84-1 and JAY 2-22-33 in neuronal culture and Caenorhabditis elegans. Mol Neurodegener2010; 5: 1–13.
31.
KrugerKFrostSMostE, et al.Exercise affects tissue lymphocyte apoptosis via redox-sensitive and fas-dependent signaling pathways. Am J Physiol Regul Integr Comp Physiol2009; 296: R1518–R1527.
32.
DaiLShenY. Insights into T-cell dysfunction in Alzheimer's disease. Aging Cell2021; 20: e13511.
33.
LiaoWIWuSYWuGC, et al.Ac2-26, an annexin A1 peptide, attenuates ischemia-reperfusion-induced acute lung injury. Int J Mol Sci2017; 18: 1771.
34.
ZhangZHuangLZhaoW, et al.Annexin 1 induced by anti-inflammatory drugs binds to NF-κB and inhibits its activation: anticancer effects in vitro and in vivo. Cancer Res2010; 70: 2379–2388.
35.
DalliJNorlingLVRenshawD, et al.Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood2008; 112: 2512–2519.
36.
LimJEKouJSongM, et al.Myd88 deficiency ameliorates β-amyloidosis in an animal model of Alzheimer's disease. Am J Pathol2011; 179: 1095–1103.
37.
FrydmanJ. Folding of newly translated proteins in vivo: the role of molecular chaperones. Annu Rev Biochem2001; 70: 603–647.
38.
TóthMESzegediVVargaE, et al.Overexpression of Hsp27 ameliorates symptoms of Alzheimer's disease in APP/PS1 mice. Cell Stress Chaperones2013; 18: 759–771.
39.
KorenJIIIJinwalUKLeeDC, et al.Chaperone signalling complexes in Alzheimer's disease. J Cell Mol Med2009; 13: 619–630.
40.
MontibellerLDe BellerocheJ. Amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD) are characterised by differential activation of ER stress pathways: focus on UPR target genes. Cell Stress Chaperones2018; 23: 897–912.
41.
WeickertSWawrzyniukMJohnL, et al.The mechanism of Hsp90-induced oligomerizaton of tau. Sci Adv2020; 6: eaax6999.
42.
BrehmeMVoisineCRollandT, et al.A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Cell Rep2014; 9: 1135–1150.
43.
ItagakiSMcGeerPAkiyamaH. Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue. Neurosci Lett1988; 91: 259–264.
44.
ZiningaTRamatsuiLShonhaiA. Heat shock proteins as immunomodulants. Molecules2018; 23: 2846.
45.
LeeCTRepaskyEA. Opposing roles for heat and heat shock proteins in macrophage functions during inflammation: a function of cell activation state?Front Immunol2012; 3: 140.
46.
El SayedNSGhoneumMH. Antia, a natural antioxidant product, attenuates cognitive dysfunction in streptozotocin-induced mouse model of sporadic Alzheimer’s disease by targeting the amyloidogenic, inflammatory, autophagy, and oxidative stress pathways. Oxid Med Cell Longev2020; 2020: 4386562.
47.
LaplanteMSabatiniDM. mTOR signaling in growth control and disease. Cell2012; 149: 274–293.
48.
DengZDongYZhouX, et al.Pharmacological modulation of autophagy for Alzheimer's disease therapy: opportunities and obstacles. Acta Pharm Sin B2022; 12: 1688–1706.
49.
WolfeDMLeeJKumarA, et al.Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. Eur J Neurosci2013; 37: 1949–1961.
50.
WhyteLSLauAAHemsleyKM, et al.Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease?J Neurochem2017; 140: 703–717.
51.
JunJYingsongJQiongL, et al.The mechanism of exercise regulating the autophagy-lysosome pathway to prevent Alzheimer's disease. Prog Biochem Biophys2023; 50: 2314–2324.
52.
HossainMIMarcusJMLeeJH, et al.Restoration of CTSD (cathepsin D) and lysosomal function in stroke is neuroprotective. Autophagy2021; 17: 1330–1348.
53.
TianLZhangKTianZY, et al.Decreased expression of cathepsin D in monocytes is related to the defective degradation of amyloid-β in Alzheimer's disease. J Alzheimers Dis2014; 42: 511–520.
54.
VidoniCFolloCSavinoM, et al.The role of cathepsin D in the pathogenesis of human neurodegenerative disorders. Med Res Rev2016; 36: 845–870.
55.
LiQLiuYSunM. Autophagy and Alzheimer’s disease. Cell Mol Neurobiol2017; 37: 377–388.
56.
LadrorUSSnyderSWWangGT, et al.Cleavage at the amino and carboxyl termini of Alzheimer's amyloid-beta by cathepsin D. J Biol Chem1994; 269: 18422–18428.
57.
YetingZYanFXueL, et al.Effects of aerobic exercise on learning, memory, and hippocampal neuromorphology in mice with Alzheimer's disease. Chin J Tissue Eng Res2023; 27: 3188–3194.
58.
HüttenrauchMBraussAKurdakovaA, et al.Physical activity delays hippocampal neurodegeneration and rescues memory deficits in an Alzheimer disease mouse model. Transl Psychiatry2016; 6: e800.
59.
GorenbergELChandraSS. The role of co-chaperones in synaptic proteostasis and neurodegenerative disease. Front Neurosci2017; 11: 248.
60.
Prado LimaMGSchimidtHLGarciaA, et al.Environmental enrichment and exercise are better than social enrichment to reduce memory deficits in amyloid beta neurotoxicity. Proc Natl Acad Sci U S A2018; 115: E2403–E2409.
61.
GratuzeMJulienJMorinF, et al.Differential effects of voluntary treadmill exercise and caloric restriction on tau pathogenesis in a mouse model of Alzheimer's disease-like tau pathology fed with Western diet. Prog Neuropsychopharmacol Biol Psychiatry2017; 79: 452–461.
62.
ChunhongCWeiWYiZ, et al.Clinical effects of aerobic training in the treatment of Alzheimer's disease. Chin J Rehabil Med2015; 30: 1131–1161.
63.
JanssensVGorisJ. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J2001; 353: 417–439.
64.
PolakisP. The many ways of Wnt in cancer. Curr Opin Genet Dev2007; 17: 45–51.
65.
BarkerNCleversH. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov2006; 5: 997–1014.
66.
HuiZLiZBiaoH, et al.The mechanism of Wnt/β-catenin signaling pathway induced Aβ clearance from brain by exercise. J Nanjing Inst Phys Educ2017; 16: 23–51.
67.
LiuSLongJYuanB, et al.SUMO Modification reverses inhibitory effects of smad nuclear interacting protein-1 in TGF-β responses. J Biol Chem2016; 291: 24418–24430.
68.
ZhangCYuYRuanL, et al.The roles of phosphodiesterase 2 in the central nervous and peripheral systems. Curr Pharm Des2015; 21: 274–290.
69.
TrabancoAABuijnstersPRomboutsFJ. Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010-present). Expert Opin Ther Pat2016; 26: 933–946.
70.
Fernández-FernándezDRosenbrockHKrokerKS. Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus. Synapse2015; 69: 484–496.
71.
BoessFGHendrixMvan der StaayFJ, et al.Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology2004; 47: 1081–1092.
72.
BalesKRPlathNSvenstrupN, et al.Phosphodiesterase inhibition to target the synaptic dysfunction in Alzheimer’s disease. Neurodegener Dis2010; 7: 57–90.
73.
TangLJiangJSongG, et al.Design, synthesis, and biological evaluation of novel 6 H-Benzo [c] chromen-6-one derivatives as potential phosphodiesterase II inhibitors. Int J Mol Sci2021; 22: 5680.
74.
ClarkJSKayedRAbateG, et al.Post-translational modifications of the p53 protein and the impact in Alzheimer’s disease: a review of the literature. Front Aging Neurosci2022; 14: 835288.
75.
MartireSMoscaLd’ErmeM. PARP-1 involvement in neurodegeneration: a focus on Alzheimer’s and Parkinson’s diseases. Mech Ageing Dev2015; 146: 53–64.
76.
NuñezGBenedictMAHuY, et al.Caspases: the proteases of the apoptotic pathway. Oncogene1998; 17: 3237–3245.
77.
TangYLiuYZhaoW, et al.Caspase-8 polymorphisms and risk of oral squamous cell carcinoma. Exp Ther Med2015; 10: 2267–2276.
78.
KumarSBudhathokiSOliveiraCB, et al.Role of the caspase-8/RIPK3 axis in Alzheimer’s disease pathogenesis and Aβ-induced NLRP3 inflammasome activation. JCI Insight2023; 8: e169054.
79.
TerlizziMDi CrescenzoVGPerilloG, et al.Pharmacological inhibition of caspase-8 limits lung tumour outgrowth. Br J Pharmacol2015; 172: 3917–3928.
80.
HenekaMTCarsonMJEl KhouryJ, et al.Neuroinflammation in Alzheimer's disease. Lancet Neurol2015; 14: 388–405.
